Galmed Pharmaceuticals Announces Pre-Clinical Study Results of Aramchol and Xtandi for Prostate Cancer; Data Showed Combination of Aramchol with Enzalutamide Resulted in Three- to Four-Fold Increase in Cell Death Compared to Enzalutamide Alone

17 Aug 2026 · 13:19 UTC

Observed price moves

GLMD+1.31%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.